BioMedPartners raises CHF75 million in first closing of healthcare venture fund

Posted: 21/04/2017

BioMedPartners has announced the first closing of BioMedInvest III, its third Guernsey-domiciled equity venture capital fund, at CHF75 million.

The healthcare venture capital fund invests in private early-to-mid-stage companies in Switzerland, Germany and neighbouring countries of the European Union.

“The continued success of BioMedInvest has clearly convinced major investors in the previous funds to commit also to BioMedInvest III. Among these are a large European institutional investor and the Berner Kantonalbank, BEKB,” says Dr Markus Hosang, General Partner at BioMedPartners.

BioMedInvest III, a collective investment scheme authorised by the Guernsey Financial Services Commission, is the third Guernsey-domiciled BioMedPartners fund administered by Louvre Fund Services. 

Collas Crill acted for BioMedInvest on the establishment of the fund, led by Group Partner Paul Wilkes.

The new fund will continue BioMedPartners’ strategy of investing in innovative biopharmaceutical, medical device and diagnostics companies.

With a target size of CHF120-150 million, BioMedInvest III plans to invest in 12 to 16 private companies. It will start to invest immediately, and the final closing is foreseen for early 2018.


Add a Comment

  • *
  • *
  • *
  • *
  • Submit
Mourant Ozannes

Want to know when we publish new content?

All you need to do is sign up for our newsletter.You'll receive a daily summary email of new items which have been published.

Please be advised that the volume of Business News articles which we publish is fairly high and you should expect to receive an email most days.

You can update your preferences at any time by registering for a blglobal.co.uk account and visiting the 'Your Profile' page.



Subscribe

It's easy to stay current with blglobal.co.uk.

Just sign up for our email updates!

Yes please! No thanks!